Navigation Links
PharmAthene Reports Third Quarter 2011 Financial and Operating Results
Date:11/9/2011

ANNAPOLIS, Md., Nov. 9, 2011 /PRNewswire/ --

Third Quarter Highlights

  • Recognized total revenue of $5.3 million
  • Awarded $5.7 million contract from Department of Defense (DoD) for nerve agent medical countermeasure program
  • Delaware Court of Chancery awarded PharmAthene 50% net profit split on worldwide sales of ST-246 and related products once SIGA realizes the first $40 million in net profits
  • Completed 1500L commercial scale-up and first cGMP manufacturing run for SparVax™

  • PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operating results for the third quarter ended September 30, 2011.

    Eric I. Richman, President and Chief Executive Officer, commented, "The third quarter was a transformative one for PharmAthene.  As we reported in September, after nearly 5 years of litigation against SIGA Technologies, the Delaware Court of Chancery issued a ruling in favor of PharmAthene.  The court awarded PharmAthene the right to receive 50% of the net profits from sales of SIGA's ST-246 smallpox antiviral therapeutic and related products over 10 years, once SIGA receives the first $40 million in net profits.

    "Based on SIGA's public disclosures, deliveries of this product to the U.S. government could occur as early as late summer 2012 or early 2013.  We believe this represents a major potential revenue stream for PharmAthene that should allow us to accelerate near-term profitability and create enhanced value for PharmAthene shareholders.  

    "Since the ruling, SIGA has subsequently filed a motion for re-argument, which is pending before the Court.  If the Court denies the motion, the parties will have 20 days from that date to submit a proposed form of final judgment, followin
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
    2. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
    3. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
    4. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
    5. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
    6. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
    7. PharmAthene Completes $6.5 Million Registered Direct Offering
    8. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    9. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    10. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
    11. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... ... September 02, 2015 , ... The ... the use of special anti-vascular endothelial growth factor agents given by injection into ... does not have a scientific protocol for the many millions diagnosed with it. ...
    (Date:9/2/2015)... , Sep. 02, 2015 ... ) has announced the addition of Jain ... Markets and Companies" to their offering. ... several technologies besides fluorescence in situ hybridization ... FISH. Molecular cytogenetics includes application of nanobiotechnology, ...
    (Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
    (Date:9/2/2015)... FRANCISCO, Calif. , Sept. 2, 2015 ... Bonnie H. Anderson , president and chief executive ... Conference on Wednesday, September 16, 2015 at 10:30 a.m. ... The live audio webcast and subsequent ... . The webcast will be available shortly after conclusion ...
    Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Veracyte to Present at Morgan Stanley Global Healthcare Conference 2
    ... Advanced Life Sciences Holdings, Inc. (OTCBB: ... and commercialization of novel drugs in the therapeutic areas ... it has suspended operations and terminated its staff due ... (Logo:   http://photos.prnewswire.com/prnh/20080218/ALSLOGO ) "We presently ...
    ... SAINT PAUL, Minn., May 5, 2011 Image Sensing Systems, ... for its first quarter ended March 31, 2011. ... first quarter was $6.1 million compared to $5.4 million for ... $2.7 million in the first quarter of 2011 compared to ...
    ... May 5, 2011 In parts of the ... often misdiagnosed. Such misdiagnosis is a waste not only of ... of another mosquito-borne viral infection called chikungunya—its high fever, joint ... mimic the clinical profile of dengue. Recovery from the acute ...
    Cached Biology Technology:Advanced Life Sciences Suspends Operations 2Image Sensing Systems Announces First Quarter Financial Results 2Image Sensing Systems Announces First Quarter Financial Results 3Image Sensing Systems Announces First Quarter Financial Results 4Image Sensing Systems Announces First Quarter Financial Results 5SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 2SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 3
    (Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
    (Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
    (Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
    Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
    ... The stem cells that produce bird feathers have been visualized ... in a scientific journey that may ultimately shed light on ... 15 issue of the journal Nature, was performed by a ... Medicine of the University of Southern California. , "What we ...
    ... drought, otherwise harmless snails likely killed off thousands of ... years. , Periwinkle snails, known to science as Littoraria ... drought, which lasted from 1999 to 2001, weakened and ... so extensively that the snails moved from finishing off ...
    ... Johns Hopkins' senior hospital epidemiologist and flu expert is ... as the best means of protecting patients and hospital ... Studies by other United States researchers show that voluntary ... year, nearly 40,000 Americans die from influenza, many of ...
    Cached Biology News:USC researchers track down the stem cells that create feathers 2USC researchers track down the stem cells that create feathers 3Research: Snails were overlooked contributors to marsh destruction 2Research: Snails were overlooked contributors to marsh destruction 3Johns Hopkins flu expert calls for mandatory vaccination of health care workers 2Johns Hopkins flu expert calls for mandatory vaccination of health care workers 3
    All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
    ...
    ...
    ... APAgene kits are designed to rapidly ... using our patented APA Technology. APAgene provides ... competitive price. All necessary ingredients are provided ... kit can be used for insert-end amplification ...
    Biology Products: